Phase 1 × NIH × Cytarabine × Clear all
NCT00098423 2013-09-30

Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
NCT00357305 2013-05-03

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
NCT00080925 2012-03-08

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
20 enrolled
NCT00004086 2009-06-09

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

National Cancer Institute (NCI)

Phase 1 Unknown